Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharma intelligence for marketing agencies

Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.

Supporting market access strategy

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Our unique strengths

Understand your clients’ world

Gain comprehensive knowledge of the global pharma market with our complete coverage.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking updates impacting the pharmaceutical industry.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

Pink Sheet: global policy and regulatory coverage

Unparalleled access to global pharma regulatory and compliance intelligence and expertise.

Key benefits:

Get a global view
Go beyond the news
Hear from news makers

Pink Sheet

US COVID Vaccine Patent Waiver Is Big, Symbolic Blow For Pharma, But The Fight Is Just Beginning

Drug manufacturers still have a variety of ways to limit the impact of the Biden administration’s historic decision. Whether the huge political loss for industry translates into more than just headline-risk or faster global COVID vaccination remains to be seen. It's also not clear whether it’s an ominous sign for other industry battles in the US, including the drug pricing debate.

View article
HBW Insight

Germany's OTC Market Struggling To Recover To Pre-Pandemic Levels

As Germany remains in lockdown, sales in its OTC market struggle to return to pre-pandemic levels, according to new data from Sempora Consulting. Meanwhile, COVID-related trends for wellness and online shopping endure, indicating some strategic priorities for OTC firms operating in the country.

View article
Scrip

Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected

Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.

View article
Scrip

Will Beovu Be A Slow-Burning Blockbuster?

Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.

View article
Citeline, Biomedtracker, Pharma Consulting, Datamonitor Heal...

COVID-19 24 hour webinar recordings

Catch up on any missed COVID-19 24 hour webinar sessions

Topic Cardiovascular Coronavirus

Full video
Generics Bulletin

Industry Steps Up To Help India Through Second Wave

As India sees a consistent rise in daily cases and deaths due to COVID-19, the off-patent industry is stepping up to make drugs affordable and available. Zydus Cadila is seeking approval for virafin, while Natco has applied for molnupiravir approval. Vaccine production and availability has also come under focus.

View article
Generics Bulletin

European Biosimilars Can Benefit From Sharing Experiences

Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.

View article
Pink Sheet

Long-Awaited EU Clinical Trials Portal Meets Major Milestone

A simplified process for registering and evaluating clinical trials promised by the EU Clinical Trial Regulation is finally set to become a reality.

View article
Scrip

Raising Corporate Taxes Would Put US Investment At Risk, J&J CFO Warns

J&J employs 3,000 more people today than it did before US corporate tax reform in 2017, CFO Wolk said, highlighting the company's US investments.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.

View article
Scrip

#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity

Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.

View article
Scrip

Will AZ Legal Notice, Clotting Incidents Cloud Serum’s Fortunes?

AstraZeneca has sent a legal notice to Indian partner Serum Institute for non-delivery of COVID-19 vaccines. Will this and the entry of a new challenger, Sputnik V, in the Indian market affect Serum’s fortunes? Will the EMA and MHRA announcement on clotting incidents related to the AZ vaccine shrink demand for the partnered vaccine?

View article
Scrip

AACR Round-Up: Zentalis, Pieris, Hookipa And Eli Lilly

Zentalis outlines promising antitumor activity associated with its WEE1 inhibitor, Phase II trials are planned for Pieris Pharmaceuticals’ fusion protein in HER2-positive cancers, while HPV-positive cancers are being targeted by Hookipa’s immunotherapeutics in arenavirus vectors, and Eli Lilly is planning early-stage clinical trials with its next-generation KRAS inhibitor.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.

View article
HBW Insight

NIH, CDC Distributing OTC COVID-19 Tests In US Study On Reducing Community Transmission

NIH pays for 2m of Quidel's QuickVue tests in a program it’s conducting with CDC to determine whether frequent self-administered testing helps reduce community transmission of SARS-CoV-2.

View article